An international comparative analysis and roadmap to sustainable biosimilar markets
Background: Although biosimilar uptake has increased (at a variable pace) in many countries, there have been recent concerns about the long-term sustainability...
He commonly talks at international conferences on issues to do with health technology assessment and pricing and reimbursement and the economics of innovation for pharmaceutical products and diagnostics. He has also acted as an expert in international arbitrations involving multinational pharmaceutical companies and was EFPIA and PhRMA’s economic expert during the DG Competition’s Sector Inquiry.
Mr. Wilsdon has completed studies for the European Commission (including DG GROW and TRADE) and the pharmaceutical industry (through EFPIA, PhRMA, and country associations such as Innovative Medicines Canada, ABPI, LIF, and IPASA) on how healthcare markets could be reformed for efficiency. He was responsible for leading an assignment for the European Commission determining whether there was a global crisis in innovation and the risks of importation. For the industry, he has undertaken assessments of health technology assessments, international reference pricing, early access agreements, managed entry agreements and many other issues.